Key result
Long-term aspirin use is linked to a ~30% reduction in colorectal cancer incidence.
Why the study?
The therapeutic roles of aspirin against tumors, including its potential antineoplastic effects, have not been fully elucidated.
Does long-term use of aspirin reduce the incidence of colorectal cancer and cancer risk?
Does long-term use of aspirin reduce the incidence of colorectal cancer and cancer risk?
Long-term use of aspirin may reduce the incidence of colorectal cancer by up to 30%, likely through anti-inflammatory mechanisms and COX2 deactivation.
Aspirin chemoprevention in colorectal cancer remains hypothesis-generating; leaves open confirmation of causality and net benefit in randomized trials.
The present review study reviewed the literature for the possible therapeutic roles of aspirin against tumors. Aspirin has various therapeutic properties among which is the anti-inflammatory property. Epidemiological studies have proved the efficacy of long term use of aspirin in reducing the incidence of colorectal cancer by up to 30%, and the cancer risk as well. Although no exact mechanism has been entirely proposed so far to explain the antineoplastic effect of aspirin against cancer, two mechanisms have been under focus, the first is related to its anti-inflammatory properties which are thought to suppress the inflammatory mediators and to inhibit carcinogenic mechanisms, and the other mechanism is through the deactivation of COX2. We would like to raise the possibility for aspirin to be regularly involved in preventive mechanisms.
No takes yet. Share an insight, caveat, or question.
Alnsour et al. (2016) conducted a review in Malignancies (Colorectal Cancer). Aspirin was evaluated. Long-term use of aspirin is associated with a reduction in the incidence of colorectal cancer by up to 30%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: